Breadcrumb

Breadcrumbs

Press Releases

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to mediainquiries@dsi.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

From To
Date Title
2020.05.29
ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung ...
PDF (184 KB)
2019.11.04
Daiichi Sankyo Files Declaratory Judgement Action Related to its Proprietary Antibody Drug Conjugat ...
PDF (132 KB)
2020.05.11
ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Positive Metastatic Gastric ...
PDF (179 KB)
2020.05.21
ENHERTU® Granted Orphan Drug Designation in the U.S. for Gastric Cancer
PDF (186 KB)
2020.08.06
Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Derux ...
PDF (133 KB)
2020.01.06
ENHERTU® Now Available in U.S. for HER2 Positive Unresectable or Metastatic Breast Cancer Following ...
PDF (253 KB)
2019.11.19
Positive Pivotal Data for Daiichi Sankyo’s DS-8201 ([Fam]-Trastuzumab Deruxtecan) in Patients with ...
PDF (181 KB)
2019.10.17
[Fam-] Trastuzumab Deruxtecan (DS-8201) Granted FDA Priority Review for Treatment of Patients with ...
PDF (171 KB)
2020.05.29
ENHERTU® Significantly Improved Tumor Response Rate and Overall Survival in HER2 Positive Metastati ...
PDF (246 KB)
2020.05.25
Daiichi Sankyo Launches ENHERTU® in Japan for Patients with HER2 Positive Unresectable or Metastati ...
PDF (256 KB)
Showing 1 - 10 of 35 results.

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...